Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14184518 | 0.91 | TSHR (1.00) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL3824883 | 0.90 | TSHR (0.92) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL12963486 | 0.86 | MEN1 (0.73) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL31037456 | 0.84 | MEN1 (0.71) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL1544971 | 0.84 | MEN1 (0.71) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL11008746 | 0.83 | CASR (0.72) | TSHRMEN1KMT2AGAAALDH1A1 | |
| Bromide SCHEMBL8684539 | 0.83 | MEN1 (0.69) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL5748764 | 0.83 | MEN1 (1.00) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL8347824 | 0.82 | MEN1 (0.68) | TSHRMEN1KMT2AGFERGAA | |
| SCHEMBL874882 | 0.82 | TSHR (0.58) | TSHRMEN1KMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1793828-A4 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | REDDYS LAB LTD DR (IN) | 2009-09-02 | — | — | EP | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1793828-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | Dr. Reddy's Laboratories Ltd. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006029075-A2 | FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-03-16 | — | — | WO | disclosed |
| US-6331555-B1 | EVALUATING SUSCEPTIBILITY OF CANCER TO COMPOUNDS WHICH INHIBIT PLATELET DERIVED GROWTH FACTOR RECEPTOR ACTIVITY | UNIVERSITY OF CALIFORNIA | 2001-12-18 | — | — | US | disclosed |
| EP-1000617-A2 | Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor | Sugen, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5990141-A | ADMINISTERING 5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID-N-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-TRIFLUORO-METHYL)PHENYL-2-BUTENAMIDE; ANTITUMOR,-CARCINOGENIC AND PROLIFERATIVE AGENTS; KINASE INHIBITORS | SUGEN INC. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5958959-A | ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-2-BUTENAMIDE | SUGEN, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5932602-A | ANTIGROWTH AGENTS; ANTITUMOR AGENT; USING AN ISOOXIDAZOLE COMPOUND | SUGEN, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5700822-A | ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ISOXAZOLE AMIDE DERIVATIOVE AND CYANO, HYDROXY, AROMATIC AMIDE DERIVATIVE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-23 | — | — | US | disclosed |
| US-5700823-A | ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)-ANILIDE OR N-(4-TRIFLUOROMETHYLPHENYL)-2-CYANO-3-HYDROXYCROTONAMIDE | SUGEN, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0804191-A1 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR | Sugen, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1993021163-A1 | QUINAZOLONES HAVING CARDIOVASCULAR ACTIVITY | ITALFARMACO S.P.A. (IT) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | TSHR 26/4885MEN1 3663/4885KMT2A 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.